These findings establish MRPS7 and MRPS23 as dual therapeutic targets capable of disrupting both tumorigenic metabolism and chemoresistance networks, offering a promising avenue for precision oncology in NPC. This evidence concerns the gene MRPS7 and nasopharyngeal carcinoma.